EP Patent

EP2332939A1 — Novel Naphthyridine derivatives and the use thereof as kinase inhibitors

Assigned to Aeterna Zentaris GmbH · Expires 2011-06-15 · 15y expired

What this patent protects

The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine/threonine…

USPTO Abstract

The present invention relates to kinase modulators of the naphthyridine type and to the preparation and use thereof as medicaments for the modulation of misdirected cellular signal transduction processes, in particular for influencing the function of tyrosine and serine/threonine kinases and for the treatment of malignant or benign tumours and other disorders based on pathological cell proliferation, such as, for example, restenosis, psoriasis, arteriosclerosis and cirrhosis of the liver.

Drugs covered by this patent

Patent Metadata

Patent number
EP2332939A1
Jurisdiction
EP
Classification
—
Expires
2011-06-15
Drug substance claim
No
Drug product claim
No
Assignee
Aeterna Zentaris GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.